In summary, our findings establish OLFM4 as a critical oncogenic driver in HNSCC progression and prognosis, demonstrating that its upregulation promotes tumor aggressiveness through enhanced proliferation, migratory, and invasive capacities while simultaneously conferring cisplatin resistance. This evidence concerns the gene OLFM4 and head and neck squamous cell carcinoma.